Inhibikase Therapeutics, Inc. (IKT)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch IKT
See up to 3 months of IKT. The 7-day demo opens the 1M and 3M ranges and puts IKT on your watchlist.
Start 7-day demoLatest IKT insider trades
About Inhibikase Therapeutics, Inc. (IKT)
The SEC lists Inhibikase Therapeutics, Inc. under CIK 0001750149, in biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
IKT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Option exercise | 2 | 43,708 | |
| Other acquisition / disposition | 2 | 36,060,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
IKT insider transactions (Form 4)
3429 Form 4 filings on record, the earliest from Oct 23, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. - 10% Owner | Other | Common Stock | 18,030,000 | - footnote F1 | - | |
| RA CAPITAL MANAGEMENT, L.P. - 10% Owner | Other | Pre-Funded Warrant (Right to Buy) | 18,030,000 | - footnote F1 | - | |
| ||||||
| Dennis N. Berman - Director | Option exercise | Common Stock | 21,854 | $1.26 | $28K | |
| Dennis N. Berman - Director | Option exercise | Stock Option (Right to Buy) | 21,854 | $0.00 | - | |
| Dennis N. Berman | Grant or award | Stock Option (Right to Buy) | 155,000 | $0.00 | - | |
| David Canner | Grant or award | Stock Option (Right to Buy) | 155,000 | $0.00 | - | |
| Arvind Kush | Grant or award | Stock Option (Right to Buy) | 155,000 | $0.00 | - | |
| Roberto Bellini | Grant or award | Stock Option (Right to Buy) | 155,000 | $0.00 | - | |
| Vincent Aurentz | Grant or award | Stock Option (Right to Buy) | 155,000 | $0.00 | - | |
| Amit Munshi | Grant or award | Stock Option (Right to Buy) | 155,000 | $0.00 | - | |
| Vincent Aurentz | Derivative | Common Stock | 255,299 footnote F1 | $0.00 | - | |
| ||||||
| Christopher Cabell - Officer | Derivative | Common Stock | 338,282 footnote F1 | $0.00 | - | |
| ||||||
| Amit Munshi | Derivative | Common Stock | 19,089 footnote F1 | $0.00 | - | |
| ||||||
| Mark T. Iwicki - Officer | Grant or award | Stock Option (Right to Buy) | 4,982,706 | $0.00 | - | |
| Christopher Cabell - Officer | Grant or award | Stock Option (Right to Buy) | 900,117 | $0.00 | - | |
| David McIntyre - Officer | Grant or award | Stock Option (Right to Buy) | 986,319 | $0.00 | - | |
| Sands Capital Life Sciences Pulse Fund II, L.P. - 10% Owner | Open-market purchase | Common Stock | 2,068,965 | $1.45 | $3.00M | |
| David Canner | Grant or award | Stock Option (Right to Buy) | 108,176 | $0.00 | - | |
| Arvind Kush | Grant or award | Stock Option (Right to Buy) | 108,176 | $0.00 | - | |
| Roberto Bellini | Grant or award | Stock Option (Right to Buy) | 108,176 | $0.00 | - | |
| Vincent Aurentz | Grant or award | Stock Option (Right to Buy) | 108,176 | $0.00 | - | |
| Amit Munshi | Grant or award | Stock Option (Right to Buy) | 108,176 | $0.00 | - | |
| Dennis N. Berman | Grant or award | Stock Option (Right to Buy) | 108,176 | $0.00 | - | |
| Christopher Cabell - Officer | Grant or award | Stock Option (Right to Buy) | 1,100,705 | $0.00 | - | |
| Vincent Aurentz | Grant or award | Stock Option (Right to Buy) | 134,427 | $0.00 | - | |
| Amit Munshi | Grant or award | Common Stock | 57,265 | $0.00 | - | |
| Mark T. Iwicki - Officer | Grant or award | Stock Option (Right to Buy) | 602,346 | $0.00 | - | |
| Roberto Bellini | Open-market purchase | Common Stock | 1,460,000 | $1.37 | $2.00M | |
| Roberto Bellini | Grant or award | Stock Option (right to buy) | 60,000 | $0.00 | - | |
| Arvind Kush | Open-market purchase | Common Stock | 145,000 | $1.37 | $199K | |
| Arvind Kush | Grant or award | Stock Option (right to buy) | 60,000 | $0.00 | - | |
| Amit Munshi | Open-market purchase | Common Stock | 365,000 | $1.37 | $500K | |
| Amit Munshi | Grant or award | Stock Option (right to buy) | 60,000 | $0.00 | - | |
| David Canner | Grant or award | Stock Option (right to buy) | 60,000 | $0.00 | - | |
Item 7.01, 9.01
Item 4.01, 9.01
Item 2.02, 9.01
Item 3.02, 9.01
IKT insider trading FAQ
What is the latest insider trade for IKT?
Inhibikase Therapeutics, Inc. (IKT) had 2 insider filings in the last 90 days, with the most recent on 2026-07-31. The full record for IKT runs to 29 Form 4 filings, the earliest from 2024-10-23. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying IKT stock?
No insider purchases of IKT were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling IKT stock?
No insider sales of IKT were filed in the last 90 days.
Where can I see IKT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects IKT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - RA CAPITAL MANAGEMENT, L.P. view on EDGAR
- - Dennis N. Berman view on EDGAR
- - Dennis N. Berman view on EDGAR
- - David Canner view on EDGAR
- - Arvind Kush view on EDGAR
- - Roberto Bellini view on EDGAR
- - Vincent Aurentz view on EDGAR
- - Amit Munshi view on EDGAR
- - Vincent Aurentz view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where IKT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow IKT with a 7-day demo
- IKT on your watchlist
- Every IKT Form 4 filing on record
- Up to 3 months of IKT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
